Intense-Modulated Radiation Therapy Reduces Chronic Diarrhea and Urinary Toxicity in Women With Cervical or Endometrial CancerSeptember 26th 2022
Intense-modulated therapy was associated with less patient-reported toxicities than conventional radiotherapy and demonstrated a comparable efficacy profile.
FDA Approves Eflapegrastim to Decrease Risk of Infection in Patients Receiving Cytotoxic ChemotherapySeptember 22nd 2022
The FDA has approved eflapegrastim to treat febrile neutropenia. The agent should be administered 24 hours following cytotoxic chemotherapy. It comes with warnings for fatal splenic rupture, acute respiratory distress syndrome, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, and myelodysplastic syndrome.
Lenvatinib Dose Escalation Is Associated With Favorable Outcomes in Patients with HCCSeptember 21st 2022
In a real-world analysis of patients with hepatocellular carcinoma, the median overall survival with lenvatinib was 9.7 months in the low-dose group and 7.6 months in the recommended-dose group.
Oncology Nurses Must Understand the Later Effects of HSCT To Provide Adequate Survivorship CareSeptember 21st 2022
In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.
Pembrolizumab Potentially Most Effective Before Surgery in High-Risk MelanomaSeptember 18th 2022
The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.
Dose-Optimized Regorafenib Provides Comparable, Safe Option for mCRCSeptember 15th 2022
Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.
Experimental Dosing Strategy With Sotorasib Plus Immunotherapy Helps Combat Hepatotoxicity in KRAS G12C+ NSCLCAugust 31st 2022
Sotorasib is often associated with a high rate of hepatotoxic events, most of which are from elevated liver enzymes. However, a lead-in dosing strategy may help address this adverse event and improve patient tolerability.
Vaginal Hormone Therapy Is Not Linked to Breast Cancer Recurrence in Post-Menopausal PatientsAugust 29th 2022
An observational study found no association between single-agent vaginal estrogen therapy or menopausal hormone therapy and increased risk of recurrence or mortality in patients with breast cancer.
New Virtual Frailty Assessments Seek to Standardize Performance Measures for Older Adults With Blood CancerAugust 27th 2022
Investigators at Dana-Farber Cancer Institute are developing a virtual frailty assessment, which combines both patient-reported outcomes and standardized performance measures.
FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-DiseaseAugust 26th 2022
Ibrutinib is now an FDA-approved treatment for patients aged 1 year or older who have chronic graft-versus-host-disease. Prescription warnings include bleeding and cardiac problems, infections, high blood pressure, a decrease in blood cell count, and tumor lysis syndrome.
Prognostic Link Between pCR and Survival Outcomes May Be Key to Personalized Medicine Efforts in Early-Stage TNBCAugust 21st 2022
At the international congress on the Future of Breast Cancer West, Hope S. Rugo highlighted the predictive value of residual cancer burden scoring in ongoing research efforts to tailor triple-negative breast cancer treatments.
Tackling the Adverse Events of ImmunotherapyAugust 17th 2022
Most patients who receive immunotherapies will experience few, if any, treatment-related adverse effects (AEs). But some patients receiving these treatments can experience serious AEs caused by an overactivation of the immune system and its effects on healthy cells.
Podsada Discusses Biomarker Testing and ADC Therapies in Breast CancerAugust 16th 2022
The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.
Evolution of Frontline VEGF TKI/Immunotherapy Treatments Propels Field of Renal Cell CarcinomaAugust 10th 2022
In a presentation at the 6th Annual School of Nursing Oncology™, Laura Wood, RN, MSN, OCN, highlights key nurse takeaways with VEGF TKI/immune checkpoint inhibitor therapy for patients with renal cell carcinoma.
Ripretinib Exhibits Better Tolerability Profile Vs Sunitinib in Advanced GIST TumorsJuly 27th 2022
An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.
Addition of Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression, Death in DLBCLJuly 23rd 2022
Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.